Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Functional dissection of ovarian aging-associated genes NDUFS5 and UBE2L3 through integrated genomic analyses and validation

ABSTRACT: Ovarian aging, culminating in menopause, involves a gradual decline in ovarian function. Genetic factors influencing age at natural menopause (ANM) especially premature ovarian insufficiency (POI) warrant further research. We employed a Bayesian framework to integrate a genome-wide association study (GWAS) on ANM (N=69,360) with an expression quantitative trait loci (eQTL) dataset (N=1,490), identifying 28 significant risk genes. Peripheral blood analysis from patients with POI and healthy controls, combined with RNA sequencing, differential gene (DEGs) expression analysis, and RT-qPCR verification, pinpointed MSH5, GAB2, NDUFS5, LST1, and UBE2L3 as top DEGs. NDUFS5 and UBE2L3 were aberrantly expressed in hydrogen peroxide or cyclophosphamide-treated human granulosa cells. Immunohistochemisty revealed decreased NDUFS5 and increased UBE2L3 expression in human ovarian samples of varying ages. NDUFS5 knockdown reduced granulosa cell proliferation and increased apoptosis in cell culture; UBE2L3 knockdown exhibited the opposite effect. Together, our findings indicate NDUFS5 and UBE2L3 as key risk genes involved in ovarian aging.

ORGANISM(S): Homo sapiens

PROVIDER: GSE288033 | GEO | 2026/01/23

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

BCAA insufficiencies lead to premature ovarian insufficiency via ceramide induced elevation of ROS

Project description:Premature ovarian insufficiency (POI) is a disease featured by early menopause before 40 years of age, accompanied by an elevation of follicle-stimulating hormone (FSH). Though POI affects many aspects of women’s health, its major causes remain unknown. Many clinical studies have shown that POI patients are generally underweight, indicating a potential correlation between POI and metabolic disorders. To understand the pathogenesis of POI, we performed metabolomics analysis on serum and identified branch chain amino acid (BCAA) insufficiency related metabolic disorders in two independent cohorts from two clinics. A low BCAA diet phenotypically reproduced the metabolic, endocrine, ovarian, and reproductive changes of POI in young C57 B6 mice. A mechanism study revealed that the BCAA insufficiency induced POI is associated with abnormal activation of the ceramide-ROS axis and consequent impairment of ovarian granulosa cell function. Significantly, dietary supplement of BCAA prevented the development of ROS-induced POI in female mice. The results of this pathogenic study will lead to the development of specific therapies for POI.

2023-03-28 | GSE215358 | GEO

BCAA insufficiency leads to premature ovarian insufficiency via ceramide-induced elevation of ROS (untargeted lipidomics)

Project description:Premature ovarian insufficiency (POI) is a disease featured by early menopause before 40 years of age, accompanied by an elevation of follicle-stimulating hormone. Though POI affects many aspects of women's health, its major causes remain unknown. Many clinical studies have shown that POI patients are generally underweight, indicating a potential correlation between POI and metabolic disorders. To understand the pathogenesis of POI, we performed metabolomics analysis on serum and identified branch-chain amino acid (BCAA) insufficiency-related metabolic disorders in two independent cohorts from two clinics. A low BCAA diet phenotypically reproduced the metabolic, endocrine, ovarian and reproductive changes of POI in young C57BL/6J mice. A mechanism study revealed that the BCAA insufficiency-induced POI is associated with abnormal activation of the ceramide-reactive oxygen species (ROS) axis and consequent impairment of ovarian granulosa cell function. Significantly, the dietary supplement of BCAA prevented the development of ROS-induced POI in female mice. The results of this pathogenic study will lead to the development of specific therapies for POI. Untargeted lipidomics is reported in the current study <a href='https://www.ebi.ac.uk/metabolights/MTBLS6249' rel='noopener noreferrer' target='_blank'>MTBLS6249</a>.Targeted metabolomics is reported in <a href='https://www.ebi.ac.uk/metabolights/MTBLS6267' rel='noopener noreferrer' target='_blank'>MTBLS6267</a>.

2024-09-26 | MTBLS6249 | MetaboLights

BCAA insufficiency leads to premature ovarian insufficiency via ceramide-induced elevation of ROS (targeted metabolomics)

Project description:Premature ovarian insufficiency (POI) is a disease featured by early menopause before 40 years of age, accompanied by an elevation of follicle-stimulating hormone. Though POI affects many aspects of women's health, its major causes remain unknown. Many clinical studies have shown that POI patients are generally underweight, indicating a potential correlation between POI and metabolic disorders. To understand the pathogenesis of POI, we performed metabolomics analysis on serum and identified branch-chain amino acid (BCAA) insufficiency-related metabolic disorders in two independent cohorts from two clinics. A low BCAA diet phenotypically reproduced the metabolic, endocrine, ovarian and reproductive changes of POI in young C57BL/6J mice. A mechanism study revealed that the BCAA insufficiency-induced POI is associated with abnormal activation of the ceramide-reactive oxygen species (ROS) axis and consequent impairment of ovarian granulosa cell function. Significantly, the dietary supplement of BCAA prevented the development of ROS-induced POI in female mice. The results of this pathogenic study will lead to the development of specific therapies for POI. Targeted metabolomics is reported in the current study <a href='https://www.ebi.ac.uk/metabolights/MTBLS6267' rel='noopener noreferrer' target='_blank'>MTBLS6267</a>.Untargeted lipidomics is reported in <a href='https://www.ebi.ac.uk/metabolights/MTBLS6249' rel='noopener noreferrer' target='_blank'>MTBLS6249</a>.

2024-09-26 | MTBLS6267 | MetaboLights

BCAA insufficiencies lead to premature ovarian insufficiency via ceramide induced elevation of ROS

2022-10-13 | PXD037353 |

Early Postnatal Alterations in Follicular Stress Response and Survival in a Mouse Model of Classic Galactosemia

Project description:Primary ovarian insufficiency (POI) is characterized by accelerated loss of primordial follicles, which results in ovarian failure and concomitant menopause before age 40. 1-3% of females in the general population are diagnosed with POI and 80% of females with the inherited disease Classic Galactosemia (CG) will develop POI. CG is caused by mutations in the GALT gene encoding the enzyme galactose-1-phosphate uridylyltransferase. While dietary restriction of galactose is lifesaving in the neonatal period, the development of severe complications including POI is not mitigated. Additionally, the pattern of follicle loss have not been completely characterized. The chronic accumulation of aberrant metabolites such as galactose-1 phosphate and galactitol are the suspected culprits in the development of the sequelae, yet the mechanisms remain elusive. Our group uses a GalT gene-trapped mouse model to study the pathophysiology of CG. Recently, we showed that alterations in the Integrated Stress Response pathway occur in the ovaries of these mice, likely contributing to the POI phenotype. Using immunofluorescent staining in whole-ovary histology at progressive ages, we saw evidence of altered Integrated Stress Response activity in granulosa cells and primordial oocytes leading to accelerated primordial follicle growth, aberrant DNA damage repair, and increased cellular stress/death. RNA-sequencing of whole ovary revealed significant alterations in cholesterol/lipid metabolism and transcriptional regulation. Overall, our findings indicate abnormal stress response results in accelerated primordial follicle activation or “burnout,” which may explain the POI phenotype of fewer primordial follicles at later ages.

2023-02-01 | GSE196454 | GEO

Inflammatory Bowel Disease Leads to Long-Term Ovarian Dysfunction via Immune-Mediated Follicular Aging

Project description:The rising global incidence of inflammatory bowel disease (IBD) is associated with reduced levels of anti-Müllerian hormone (AMH), a key biomarker for premature ovarian insufficiency (POI), highlighting reproductive risks for women of childbearing age. To investigate the connection between IBD and ovarian aging, we used a dextran sodium sulfate (DSS)-induced mouse model of IBD and assessed reproductive outcomes, including ovarian reserve, folliculogenesis, hormone profiles, and estrous cyclicity. Transcriptomic analysis of ovarian tissue showed that IBD upregulates genes associated with aging. Gene Ontology enrichment pointed to signaling pathways involved in cellular senescence, oxidative stress response, and senescence-associated secretory phenotypes. By integrating our ovarian transcriptomic data with single-cell RNA-seq datasets from young (3-month) and aged (9-month) mouse ovaries, we found significant parallels between IBD-induced transcriptional changes and natural ovarian aging. Flow cytometry confirmed elevated levels of T cells, CD8+ T cells, and macrophages in the ovaries, indicating localized immune activation. Similar systemic immune changes were observed in peripheral blood mononuclear cells, with expanded T cell and macrophage populations. TUNEL assays and qPCR further validated accelerated ovarian aging in IBD mice, showing increased granulosa cell apoptosis and upregulated aging-related markers. Notably, even after an 89-day recovery period following DSS treatment, persistent deficits in follicular counts, hormonal balance, and estrous regularity indicated irreversible ovarian dysfunction. Our findings demonstrate that IBD triggers ovarian inflammation, depletes ovarian reserve, and accelerates aging processes, leading to long-term reproductive impairment. This study elucidates the mechanistic links between IBD and POI, providing insights for therapeutic strategies to mitigate fertility risks in affected women.

2025-02-17 | GSE289404 | GEO

HO-1 modulates ferroptosis via ROS-mediated mitochondrial dysfunction in cyclophosphamide -induced ovarian granulosa cells

Project description:Abnormal granulosa cells (GCs) death contributes to cyclophosphamide (CTX) -induced primary ovarian insufficiency (POI). To investigate the contribution of GCs in POI, gene profiles of GCs exposed to CTX were assessed using RNA-Seq and bioinformatics analysis. The results showed the differentially expressed genes (DEGs) are enriched in ferroptosis-related pathway, which is correlated with the upregulated Heme oxygenase 1 (HO-1) and downregulated glutathione peroxidase-4 (GPX4). Using CTX-induced cell culture (COV434 and KGN cells), the levels of iron, reactive oxygen species (ROS), lipid peroxide, mitochondrial superoxide, mitochondrial morphology and mitochondrial membrane potential (MMP) were detected by DCFDA, MitoSOX, C11-BODIPY, MitoTracker, Nonylacridine Orange (NAO), JC-1 and transmission electron microscopy respectively. The results showed that iron overload and disrupting ROS, including cytoROS, mtROS and lipROS homeostasis by HO-1 upregultion could induce ferroptosis via mitochondrial dysfunction in CTX-induced GCs. Moreover, HO-1 inhibition could suppress ferroptosis induced GPX4 depletion. This implies the role of ROS in CTX-induced ferroptosis and highlighted the effect of HO-1 modulators of improving CTX-induced ovarian damage, which may provide a theoretical basis for preventing or restoring GC and ovarian function in patients with POI.

2023-10-30 | GSE243720 | GEO

Targeted Metabolomics Study: The Association Between Ovarian Function and Amino Acid Level Changes in Breast Cancer Patients Before and After Chemotherapy.

Project description:Cyclophosphamide (CTX) is a primary medicine for curing breast cancer which often caused premature ovarian insufficiency (POI). Our recent publication reveals that CTX induced POI by promoting the expression of SLC1A4, a transporter of serine efflux, in ovarian granulosa cells (GCs). Here, we report that there is a closed connection between the reduction of serum serine and ovarian hypofunction in the breast cancer patients treated with CTX or women of childbearing age who are suffered from the staying-up-late. Additionally, we observe that dietary serine supplementation protects mice from CTX-induced POI without altering its anti-breast cancer. Furthermore, we demonstrate that the elevated serine promoted S1P synthesis, and in turn, inhibit the nuclear translocation of Nrf2 and consequent HO-1 expression, to suppress ferroptosis in GCs. Our study reveal that the chemotherapy-induced or idiopathic POI shared the same mechanisms, indicating that serine is a critical factor for maintaining ovarian function.

2025-12-23 | MTBLS13561 | MetaboLights

Serine inhibits granulosa cell ferroptosis to maintain ovarian function

Project description:Cyclophosphamide (CTX) is a primary medicine for curing breast cancer which often caused premature ovarian insufficiency (POI). Our recent publication revealed that CTX induced POI by promoting the expression of SLC1A4, a transporter of serine efflux, in ovarian granulosa cells (GCs). Here, we reported that there was a closed connection between the reduction of serum serine and ovarian hypofunction in the breast cancer patients treated with CTX or women of childbearing age who were suffered from the staying-up-late. Additionally, we observed that dietary serine supplementation protected mice from CTX-induced POI without altering its anti-breast cancer. Furthermore, we demonstrated that the elevated serine promoted S1P synthesis, and in turn, inhibited the nuclear translocation of Nrf2 and consequent HO-1 expression, to suppress ferroptosis in GCs. Our study revealed that the chemotherapy-induced or idiopathic POI shared the same mechanisms, indicating that serine was a critical factor for maintaining ovarian function.

2025-12-23 | GSE314714 | GEO

Gene Expression Analysis From Rat Models of Premature Ovarian Insufficiency Treated with Intraovarian Injection of Platelet Rich Plasma

Project description:Premature ovarian insufficiency (POI) has become a focus of many reproductive studies recently due to its long-life menopause-like symptoms in young women. It may affect up to three of a hundred women under 40 years. The possible causes include genetic diseases, infections, autoimmune disorders and iatrogenic events such as radiotherapy and chemotherapy. Recent studies investigating the regenerative dynamic potential of the ovaries demonstrate that follicular growth could be stimulated when an adequate ovarian environment is restored. This restoration can be achieved employing factors of known regenerative potential such as stem cells, or growth factors of platelet rich plasma (PRP), artificial ovary, ovarian transplantation, and mitochondrial replacement therapy. The emergence of autologous platelet-rich plasma (PRP) therapy reflects a break-through for POI patients, since the approach is the most ethical-friendly, the cheapest, the least invasive and limited adverse effects. Therefore, it has the highest potential to be applied in clinical routine practice. Nevertheless, the complex mechanism of PRP components’ on the ovary, especially in term of folliculogenesis, remains to be deciphered. Furthermore, it is necessary to clarify to what extent they impact the gene or protein targets that play important role in ovarian rejuvenation after POI. We report raw fastq data of Sprague Dawley rat models of POI in four treatment groups and one control to evaluate the effect of intraovarian injection of PRP on POI rat models. This report is a part of animal study regarding the effect of intraovarian injection of PRP on ovarian function recovery in POI rat models (unpublished study). The data collected from this study will be used to investigate how PRP induce the ovarian rejuvenation and to analyse transcriptomic changes after PRP treatment on chemotherapy-induced POI animal models.

2025-05-31 | GSE266521 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data